ClinicalTrials.gov
ClinicalTrials.gov Menu

Differential Clinical and Serologic Response in Psoriasis and Psoriatic Arthritis to Drug Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00451243
Recruitment Status : Completed
First Posted : March 23, 2007
Last Update Posted : March 23, 2007
Sponsor:
Information provided by:
National Taiwan University Hospital

March 22, 2007
March 23, 2007
March 23, 2007
January 2005
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Differential Clinical and Serologic Response in Psoriasis and Psoriatic Arthritis to Drug Treatment
Differential Clinical and Serologic Response in Psoriasis and Psoriatic Arthritis to Drug Treatmen
Psoriasis is a multifactorial cutaneous disorders which affects about 100000 patients in Taiwan. Psoriatic arthritis is also present in about 20~30 percents. Many drugs have been shown to aggravate psoriasis including drugs used in the treatment of psoriatic arthritis. On the contrary, anti-psoriatic drugs are also known to aggravate or induce psoriatic arthritis. Psoriasis and psoriatic arthritis are believed to share the same pathogenic lymphocytes, but the differential responses to drugs are intriguing. This also causes problems in the treatment of psoriasis and psoriatic arthritis. Recently different serologic markers have been found for the assessment of psoriasis and psoriatic arthritis. Recent genetic study showed a different genetic susceptibility genes. We tested the serologic responses of three new biologic drugs used in the treatment of psoriasis and psoriatic arthritis. Paired blood samples of the same patients before and after 12 weeks of treatment were used. IL6 decreased after alefacept and etanercept but was increased after efalizumab treatment without statistical significance (Paired t test: 0.3336、0.2773、0.5904)。IL-8 decreased after etanercept but increased after efalizumab and alefacept without statistical significance (Paired t test: 0.4031、0.6749、0.2998)。IL10 decreased after efalizumab and etanercept, but increased significantly after alefacept treatment (Paired t test: 0.7254、0.5123、0.0350)。None of the treatment has a significant effect on TNF-alpha. HC10 decreased after alefacept and efalizumab,but increased after etanercept treatmentwithout statistical significance (Paired t test: 0.6589、0.1576、0.1988).
Not Provided
Observational
Observational Model: Case Control
Time Perspective: Cross-Sectional
Time Perspective: Retrospective/Prospective
Not Provided
Not Provided
Not Provided
Not Provided
Psoriatic Arthritis
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20
Same as current
June 2005
Not Provided

Inclusion Criteria:

  • Clinical diagnosis of psoriasis
Sexes Eligible for Study: All
Child, Adult, Older Adult
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00451243
9361701244
9361701244
Not Provided
Not Provided
Not Provided
Not Provided
National Taiwan University Hospital
Not Provided
Study Chair: TSEN-FANG Tsai TSEN-FANG Tsai
National Taiwan University Hospital
December 2004